Background: Bone marrow (BM) involvement defines advanced-stage Hodgkin lymphoma and thus has impact on the assignment to treatment. Our aim was to evaluate whether the established BM biopsy may be omitted in patients if 18 Ffluorodeoxyglucose positron emission tomography (PET) scanning is carried out during staging.
Introduction
Hodgkin lymphoma is a haematological malignancy, which can be successfully treated with modern therapy regimens. In contrast to early-stage disease, which commonly responds well to a less toxic combination of chemotherapy and involved field radiation, advanced-stage Hodgkin lymphoma requires extended cytotoxic treatment [1] [2] [3] [4] [5] . Accurate staging is therefore crucial in the context of risk-adapted treatment strategies.
Bone marrow (BM) involvement is considered a sign of generalized disease and influences therapy selection, as it allocates patients to stage IV according to the Ann Arbor classification [6] . From the 1970s until recently, BM biopsy was regarded as the gold standard for assessing BM status [7] . This invasive procedure is, however, painful for the patient and carries the risk of severe complications [8] . Moreover, the information it yields applies to only a very small portion of the BM.
Over the last 20 years, 18 F-fluorodeoxyglucose (FDG) positron emission tomography (PET) in combination with computed tomography (CT) has become an established tool in the staging of lymphoma patients [9] [10] [11] [12] [13] [14] . Several working groups have therefore retrospectively studied the utility of PET/CT for detecting BM involvement. The superior sensitivity of this diagnostic tool when compared with BM biopsy was reported to be particularly marked for Hodgkin lymphoma [15] [16] [17] [18] .
Based on data collected prospectively within the German Hodgkin Study Group (GHSG) trials HD16, HD17, and HD18, we examined the value of PET scans for identifying BM involvement. Moreover, our aim was to evaluate whether BM biopsy may be omitted in Hodgkin lymphoma patients if PET scanning is carried out during staging.
Patients and methods

Analysis set
The analysis set was based on 832 patients with newly diagnosed biopsyproven Hodgkin lymphoma who underwent PET scanning in addition to BM biopsy during staging and were recruited for one of the following open-label, randomised, phase III GHSG trials between May 2008 and December 2015 ( Figure 1 3. HD18 for advanced-stage disease (stage IIB with large mediastinal mass or extra-nodal involvement, III, and IV) [5] .
HD16, HD17, and HD18 have been approved by the ethics committees of all participating centres and were conducted according to the Declaration of Helsinki. In compliance with the Good Clinical Practice guidelines of the International Conference on Harmonization, subjects gave written informed consent before inclusion. While a BM biopsy was recommended for all patients, PET imaging was not mandatory at staging.
BM biopsy
Unilateral BM biopsy was routinely obtained from the iliac bone and interpretation carried out by experienced haemato-pathologists. Only biopsy-proven BM involvement allocated patients to disease stage IV, as PET was not accepted for the assessment of BM status when conducting the HD16, HD17, and HD18 trials. Together with other diagnostic findings, biopsy results were reported to the GHSG trial coordination centre.
Central PET review
A multidisciplinary panel of experts from medical oncology, nuclear medicine, radiation oncology, and radiology carried out a central review of all available PET scans, as well as CT, magnetic resonance (MR), and X-ray images. Baseline PET examinations were assessed visually and rated positive for BM involvement if at least one site of focal uptake within the skeleton had an intensity exceeding that in the liver and could not be attributed to any other cause (e.g. bone cysts or elevated uptake caused by BM biopsy). The multi-trial review board categorized BM involvement as unifocal, bifocal, trifocal, or multifocal (!four FDG-avid BM lesions) and additionally recorded the lesion locations. All cases with diffusely increased skeletal FDG uptake higher than in the liver were documented but not interpreted as BM involvement. Moreover, follow-up PET scans after two (HD16, HD18) or four cycles of chemotherapy (HD17) were evaluated to confirm the initial findings, as only skeletal FDG uptake that remitted in parallel with nodal response on treatment was considered to represent BM involvement.
Statistical analysis
All patient characteristics were obtained from the study database and analysed using descriptive statistics. To establish how representative our sample was, we compared the baseline features of all included subjects with those of patients not evaluated for this study by conducting exact Fisher and Wilcoxon rank-sum tests. Sensitivity, specificity, positive predictive, and negative predictive value of PET for detecting BM involvement as well as the respective 95% exact binomial confidence intervals (CI) were calculated using the biopsy results as reference standard. In a second step, the diagnostic performance was assessed considering both PET findings and BM biopsy as gold standard. Moreover, the group of patients showing BM involvement on PET was compared with subjects without any FDG-avid BM lesions in relation to a series of clinical parameters by exact Fisher and Wilcoxon rank-sum tests. All statistical calculations were carried out using SAS version 9.4 (SAS Institute, Cary, NC) and P-values of <0.05 considered to be statistically significant.
Results
Patients
The median age of the 832 patients studied was 32 years (range 18-75) with a male-to-female ratio of 1.4. Of these, 791 (95%) underwent PET/CT imaging, 31 (4%) PET alone, and 10 (1%) PET/MR. Subjects with a baseline PET scan that was available to the central review panel were recruited significantly more often by university hospitals and in median at a later date than patients not analysed within this study (P <0.001 each). Among analysed subjects, 156 (19%) had a large mediastinal mass while 310 of 831 (37%) presented with high erythrocyte sedimentation rates (ESR). Moreover, extra-nodal involvement was identified in 110 patients (13%) and more than three involved lymph node areas were found in 520 (63%) cases. A total of 317 subjects (38%) presented with B symptoms. A total of 377 subjects were excluded due to revised Hodgkin lymphoma diagnosis (n¼34), missing documentation of BM biopsy (n¼47), or unavailable interim PET scans (n¼296). distribution across patients from the different trials are provided in Table 1 .
BM biopsy and PET findings
Of 20 cases with positive BM biopsy (2%), 19 were detected by PET. One patient had positive BM biopsy while showing only diffusely increased FDG uptake within the skeleton. In total, PET found 129 subjects (16%) with focal BM lesions and therefore identified 110 additional cases who would have been considered negative by biopsy (Table 2) . A unifocal pattern was observed in 43 patients with BM involvement according to PET (33%), a bifocal in 17 (13%), a trifocal in 11 (9%), and a multifocal in 58 (45%). All FDG-avid BM lesions responded to treatment: While six subjects still had focally enhanced BM FDG uptake at interim PET imaging, none of them presented with BM lesions after completion of chemotherapy. Detailed information regarding the relationship between FDG uptake pattern and biopsy results can be found in Table 3 .
Diffusely increased FDG uptake within the skeleton was documented in 152 patients (18%). According to PET findings, these subjects were considered negative with regard to BM involvement as none of them showed focal BM lesions.
Association with clinical characteristics
Patients with BM involvement on PET had a significantly higher frequency of B symptoms, elevated ESR levels, extra-nodal disease, involvement of three or more nodal areas, less favourable international prognostic scores, and advanced clinical stages. Moreover, the mean haemoglobin level and lymphocyte count were found to be significantly lower in this group. A comparison of further baseline features is presented in Table 4 .
Diagnostic performance
When regarding positive BM biopsy as the reference standard, PET showed a sensitivity, specificity, positive predictive, and negative predictive value of 95.0% (95% CI 75.1% to 99.9%), 86.5% (95% CI 83.9% to 88.7%), 14.7% (95% CI 9.1% to 22.0%), and 99.9% (95% CI 99.2% to 100%), respectively.
Considering both BM biopsy and PET findings as gold standard, the sensitivity, specificity, positive predictive, and negative predictive value of PET were 99.2% (95% CI 95.8% to 100%), 100% (95% CI 99.5% to 100%), 100% (95% CI 97.2% to 100%), and 99.9% (95% CI 99.2% to 100%), respectively.
Discussion
Our study on the value of BM biopsy in Hodgkin lymphoma patients staged by PET yielded the following major findings: First, baseline PET imaging identifies biopsy-proven BM involvement with high sensitivity. Second, with its excellent negative predictive value, PET is a highly accurate and reliable tool for exclusion of BM involvement.
Our findings are in line with observations of previous studies investigating the accuracy of PET-based BM assessment: In the RATHL trial, fewer than 1% of subjects had biopsy-confirmed BM involvement while showing no marrow lesions on PET, from which the authors inferred that BM biopsy is no longer needed within routine staging of Hodgkin lymphoma patients [14] . The retrospective analysis by El-Galaly et al. included a large number of patients from four Danish centres and reported PET/CT to identify biopsy-proven BM involvement with a sensitivity and negative predictive value of 85% and 99%, respectively [16] . In the study of Weiler-Sagie et al., the sensitivity and negative predictive value were 97% and 99%, respectively [17] . Purz et al. evaluated the value of PET for detecting BM involvement prospectively and found a sensitivity as well as negative predictive value of 100% in their paediatric cohort [19] .
With the Cotswold modifications to the Ann Arbor classification, invasive procedures have been omitted from routine staging of Hodgkin lymphoma, while BM biopsy has remained in the work-up until recently [7] . However, this diagnostic tool only examines a very small portion of the BM and may consequently miss patchy involvement due to sampling errors. When compared with bilateral BM biopsy, involvement was reported to be missed by unilateral biopsy in $20% of cases [20, 21] . In contrast, PET examines the entire BM and is able to detect BM involvements beyond the iliac bone (supplementary Figure S1 , available at Annals of Oncology online). According to our findings, BM biopsy may substantially underestimate the actual incidence of BM involvement. It therefore appears somehow questionable to investigate the diagnostic accuracy of PET using unilateral biopsy as reference. The low positive predictive value of PET when compared with BM biopsy most probably resulted from the high number of patients with BM involvement not detected by biopsy.
We observed that staging with PET allows more reliable assessment of the BM status particularly in subjects with fewer focal lesions. However, since the detection of BM involvement allocates patients to Ann Arbor stage IV, PET can lead to treatment intensification in individual subjects, without any improvement in outcome having been shown so far. In our cohort, only 1% of otherwise early-stage patients had BM involvement according to PET. Thus, positive PET findings do not influence assignment to therapy in the vast majority of patients.
The observation that most of the PET-detected BM lesions responded rapidly to treatment may be explained by the use of dose-escalated bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP esc ). Nevertheless, it should be taken into account that the present analysis was not appropriate for comparison of the highly effective BEACOPP esc with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), as none of our patients with BM involvement received ABVD only.
Diffusely increased BM FDG uptake is a common finding in the initial staging of Hodgkin lymphoma. In our cohort, the number of patients showing this uptake pattern (18%) was higher than reported by previous studies that were based on an evaluation of nuclear medicine reports only. In contrast, Zwarthoed et al. reviewed PET images for their analysis and observed an incidence of 29% [22] . Even though one of our subjects with diffusely increased FDG uptake had a positive BM biopsy, we agree with the authors of previous studies that this uptake pattern is best interpreted as a sign of benign changes (inflammatory processes, red marrow hyperplasia due to anaemia) [23, 24] . However, in rare cases, it may conceal focal lesions and thus lead to falsenegative PET results [25] .
Shortcomings of the present analysis should be mentioned: First, we cannot prove FDG-avid BM lesions to actually represent lymphoma infiltration, as directed biopsies were not taken. Nevertheless, our assumption is strongly supported by the observation that all lesions completely remitted on PET scans during the course of therapy. Second, the present analysis is retrospective in nature and pretreatment PET imaging was not mandatory for the trials evaluated. However, baseline characteristics of patients with and without initial PET do not indicate a relevant bias. On the other hand, a major strength of our study was the large number of patients that we were able to investigate and who have been treated within international, multicentre, and controlled clinical trials. Moreover, as PET interpretation was carried out by a central panel of experts, the reported findings can be considered very reliable.
In conclusion, PET appears to identify BM lesions with a higher sensitivity than routine biopsy of the iliac bone. We can rely on the excellent sensitivity and negative predictive value of PET irrespective of the gold standard chosen for calculation. Biopsy-based confirmation of single FDG-avid BM lesions hardly seems justified in general, but should be considered in subjects in whom BM involvement is leading to upstaging and subsequently more intensive treatment. Importantly, our findings strongly support to protect patients with negative PET results from the painful procedure of BM biopsy. 
